Axitinib 1 mg, 5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 1 mg, 5 mg

Reference Brands: Inlyta®(EU & US)

Category: Oncology Cancer Care

Axitinib 1 mg and 5 mg film-coated tablets, a VEGF receptor tyrosine kinase inhibitor for advanced renal cell carcinoma, for hospital oncology pharmacies, tender buyers and specialist distributors.

Product Description:

Axitinib is an oral tyrosine kinase inhibitor that selectively blocks vascular endothelial growth factor receptors 1, 2 and 3. These receptors drive the new blood vessels tumours need, so blocking them limits tumour blood supply. This page lists film-coated tablets at 1 mg and 5 mg. The 5 mg tablet is the usual starting dose, taken twice a day about 12 hours apart, and the 1 mg tablet lets prescribers adjust the dose in small steps.

Axitinib is approved for advanced renal cell carcinoma after failure of one prior systemic therapy, and in the US and EU also first line with pembrolizumab or avelumab. Tablets are swallowed whole, with or without food. Hypertension is common, so blood pressure is checked throughout. Other precautions include thyroid dysfunction, proteinuria, bleeding, clots and impaired wound healing, so dosing pauses before planned surgery. Strong CYP3A4/5 inhibitors and inducers, and grapefruit juice, should be avoided. Effective contraception is needed.

Sourcing notes. Axitinib is a prescription-only oncology medicine. Registration usually needs a full CTD or ACTD dossier with bioequivalence data, and patent and data protection status differs by market, so confirm it before quoting. Tablets come in blisters or bottles; check stability data suits hot, humid destinations. Many hospitals handle oral targeted anticancer drugs under hazardous medicines policies, so ask for safety data sheets and clear hazard labelling. Request a CoA per batch with impurities and dissolution, a GMP certificate and a CoPP. Specify strength and pack.